vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and WARRIOR MET COAL, INC. (HCC). Click either name above to swap in a different company.
WARRIOR MET COAL, INC. is the larger business by last-quarter revenue ($458.6M vs $281.3M, roughly 1.6× Guardant Health, Inc.). WARRIOR MET COAL, INC. runs the higher net margin — 15.8% vs -45.7%, a 61.5% gap on every dollar of revenue. On growth, WARRIOR MET COAL, INC. posted the faster year-over-year revenue change (52.1% vs 39.4%). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 7.5%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Warrior Met Coal, Inc. (ticker HCC) is a U.S.-headquartered mining enterprise that produces and distributes high-grade metallurgical coal, a key raw material for steel production. It serves steel manufacturers and industrial clients across core markets including North America, Europe, and Asia.
GH vs HCC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $458.6M |
| Net Profit | $-128.5M | $72.3M |
| Gross Margin | 64.6% | 36.7% |
| Operating Margin | -43.0% | 17.3% |
| Net Margin | -45.7% | 15.8% |
| Revenue YoY | 39.4% | 52.1% |
| Net Profit YoY | -15.8% | — |
| EPS (diluted) | $-1.01 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $458.6M | ||
| Q4 25 | $281.3M | $384.0M | ||
| Q3 25 | $265.2M | $328.6M | ||
| Q2 25 | $232.1M | $297.5M | ||
| Q1 25 | $203.5M | $299.9M | ||
| Q4 24 | $201.8M | $297.5M | ||
| Q3 24 | $191.5M | $327.7M | ||
| Q2 24 | $177.2M | $396.5M |
| Q1 26 | — | $72.3M | ||
| Q4 25 | $-128.5M | $23.0M | ||
| Q3 25 | $-92.7M | $36.6M | ||
| Q2 25 | $-99.9M | $5.6M | ||
| Q1 25 | $-95.2M | $-8.2M | ||
| Q4 24 | $-111.0M | $1.1M | ||
| Q3 24 | $-107.8M | $41.8M | ||
| Q2 24 | $-102.6M | $70.7M |
| Q1 26 | — | 36.7% | ||
| Q4 25 | 64.6% | 29.5% | ||
| Q3 25 | 64.7% | 27.1% | ||
| Q2 25 | 65.0% | 23.9% | ||
| Q1 25 | 63.3% | 18.1% | ||
| Q4 24 | 61.6% | 23.1% | ||
| Q3 24 | 61.1% | 29.3% | ||
| Q2 24 | 59.1% | 34.1% |
| Q1 26 | — | 17.3% | ||
| Q4 25 | -43.0% | 9.0% | ||
| Q3 25 | -37.3% | 6.3% | ||
| Q2 25 | -45.9% | 2.6% | ||
| Q1 25 | -54.6% | -5.8% | ||
| Q4 24 | -62.4% | -1.4% | ||
| Q3 24 | -61.3% | 11.9% | ||
| Q2 24 | -56.8% | 17.9% |
| Q1 26 | — | 15.8% | ||
| Q4 25 | -45.7% | 6.0% | ||
| Q3 25 | -35.0% | 11.1% | ||
| Q2 25 | -43.0% | 1.9% | ||
| Q1 25 | -46.8% | -2.7% | ||
| Q4 24 | -55.0% | 0.4% | ||
| Q3 24 | -56.3% | 12.7% | ||
| Q2 24 | -57.9% | 17.8% |
| Q1 26 | — | $1.37 | ||
| Q4 25 | $-1.01 | $0.43 | ||
| Q3 25 | $-0.74 | $0.70 | ||
| Q2 25 | $-0.80 | $0.11 | ||
| Q1 25 | $-0.77 | $-0.16 | ||
| Q4 24 | $-0.90 | $0.02 | ||
| Q3 24 | $-0.88 | $0.80 | ||
| Q2 24 | $-0.84 | $1.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $233.2M |
| Total DebtLower is stronger | $1.5B | $154.4M |
| Stockholders' EquityBook value | $-99.3M | — |
| Total Assets | $2.0B | $2.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $233.2M | ||
| Q4 25 | $378.2M | $300.0M | ||
| Q3 25 | $580.0M | $336.3M | ||
| Q2 25 | $629.1M | $383.3M | ||
| Q1 25 | $698.6M | $454.9M | ||
| Q4 24 | $525.5M | $491.5M | ||
| Q3 24 | $585.0M | $583.2M | ||
| Q2 24 | $933.7M | $709.0M |
| Q1 26 | — | $154.4M | ||
| Q4 25 | $1.5B | $154.3M | ||
| Q3 25 | $1.1B | $154.1M | ||
| Q2 25 | $1.1B | $153.9M | ||
| Q1 25 | $1.1B | $153.8M | ||
| Q4 24 | $1.1B | $153.6M | ||
| Q3 24 | — | $153.5M | ||
| Q2 24 | — | $153.3M |
| Q1 26 | — | — | ||
| Q4 25 | $-99.3M | $2.1B | ||
| Q3 25 | $-354.5M | $2.1B | ||
| Q2 25 | $-305.5M | $2.1B | ||
| Q1 25 | $-250.8M | $2.1B | ||
| Q4 24 | $-139.6M | $2.1B | ||
| Q3 24 | $-60.1M | $2.1B | ||
| Q2 24 | $-1.6M | $2.0B |
| Q1 26 | — | $2.8B | ||
| Q4 25 | $2.0B | $2.8B | ||
| Q3 25 | $1.3B | $2.7B | ||
| Q2 25 | $1.3B | $2.6B | ||
| Q1 25 | $1.3B | $2.6B | ||
| Q4 24 | $1.5B | $2.6B | ||
| Q3 24 | $1.5B | $2.6B | ||
| Q2 24 | $1.6B | $2.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.07× | ||
| Q3 25 | — | 0.07× | ||
| Q2 25 | — | 0.07× | ||
| Q1 25 | — | 0.07× | ||
| Q4 24 | — | 0.07× | ||
| Q3 24 | — | 0.07× | ||
| Q2 24 | — | 0.07× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | — |
| Free Cash FlowOCF − Capex | $-54.2M | — |
| FCF MarginFCF / Revenue | -19.3% | — |
| Capex IntensityCapex / Revenue | 9.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-26.4M | $76.1M | ||
| Q3 25 | $-35.4M | $104.7M | ||
| Q2 25 | $-60.3M | $37.5M | ||
| Q1 25 | $-62.7M | $10.9M | ||
| Q4 24 | $-64.5M | $54.2M | ||
| Q3 24 | $-51.1M | $62.2M | ||
| Q2 24 | $-94.0M | $147.0M |
| Q1 26 | — | — | ||
| Q4 25 | $-54.2M | — | ||
| Q3 25 | $-45.8M | — | ||
| Q2 25 | $-65.9M | — | ||
| Q1 25 | $-67.1M | — | ||
| Q4 24 | $-83.4M | — | ||
| Q3 24 | $-55.3M | — | ||
| Q2 24 | $-99.1M | — |
| Q1 26 | — | — | ||
| Q4 25 | -19.3% | — | ||
| Q3 25 | -17.3% | — | ||
| Q2 25 | -28.4% | — | ||
| Q1 25 | -33.0% | — | ||
| Q4 24 | -41.3% | — | ||
| Q3 24 | -28.9% | — | ||
| Q2 24 | -55.9% | — |
| Q1 26 | — | — | ||
| Q4 25 | 9.9% | — | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | 2.4% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 9.4% | — | ||
| Q3 24 | 2.2% | — | ||
| Q2 24 | 2.9% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.31× | ||
| Q3 25 | — | 2.86× | ||
| Q2 25 | — | 6.70× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 47.68× | ||
| Q3 24 | — | 1.49× | ||
| Q2 24 | — | 2.08× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
HCC
| Sales | $448.5M | 98% |
| Other revenues | $10.1M | 2% |
